NAV

Solithromycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Solithromycin
DrugBank Accession Number
DB09308
Background

Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 845.0088
Monoisotopic: 844.474620535
Chemical Formula
C43H65FN6O10
Synonyms
  • Solithromycin
External IDs
  • CEM 101
  • CEM-101
  • OP 1068
  • OP-1068
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for the treatment of community-acquired pneumonia (CAP).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Solithromycin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Solithromycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Solithromycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Solithromycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Solithromycin.
Food Interactions
Not Available

Categories

ATC Codes
J01FA16 — Solithromycin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Phenyl-1,2,3-triazoles / Aniline and substituted anilines / Oxazolidinones / Oxanes / Alpha-haloketones / Carbamate esters / Heteroaromatic compounds / 1,2-aminoalcohols / Trialkylamines / Secondary alcohols
show 15 more
Substituents
1,2,3-triazole / 1,2-aminoalcohol / Acetal / Alcohol / Alkyl fluoride / Alkyl halide / Alpha-haloketone / Amine / Amino acid or derivatives / Aminoglycoside core
show 37 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9U1ETH79CK
CAS number
760981-83-7
InChI Key
IXXFZUPTQVDPPK-ZAWHAJPISA-N
InChI
InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
IUPAC Name
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyl-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone
SMILES
[H][C@]12N(CCCCN3C=C(N=N3)C3=CC(N)=CC=C3)C(=O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@@](C)(F)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OC

References

General References
  1. Reinert RR: Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother. 2004 Jun;53(6):918-27. Epub 2004 Apr 29. [Article]
  2. Menache D: Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol. 1991 Jan;28(1):31-8. [Article]
  3. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN: Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7. [Article]
  4. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC: In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010 Jan;54(1):230-8. doi: 10.1128/AAC.01123-09. Epub 2009 Nov 2. [Article]
  5. Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN: CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2010 Apr;66(4):393-401. doi: 10.1016/j.diagmicrobio.2009.10.013. [Article]
  6. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M: Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021. [Article]
  7. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS: Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010 Dec;54(12):4961-70. doi: 10.1128/AAC.00860-10. Epub 2010 Sep 20. [Article]
PubChem Compound
25242512
PubChem Substance
310265196
ChemSpider
25056854
ChEMBL
CHEMBL1232510
ZINC
ZINC000095627834
PDBe Ligand
EM1
Wikipedia
Solithromycin
PDB Entries
4www / 8e3o

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)2
3CompletedTreatmentUncomplicated Urogenital Gonorrhea1
2CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2CompletedTreatmentNon Alcoholic Steatohepatitis (NASH)1
2CompletedTreatmentUncomplicated Urogenital Gonorrhea1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0167 mg/mLALOGPS
logP4.22ALOGPS
logP5.76Chemaxon
logS-4.7ALOGPS
pKa (Strongest Acidic)12.83Chemaxon
pKa (Strongest Basic)8.9Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count12Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area197.87 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity230.73 m3·mol-1Chemaxon
Polarizability90.81 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0000000090-61fa4c11b294e639c477
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0000000190-7f9a8d6a7e4d061d8ab9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-1730003390-768ca8733c26a9b7f90b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-006x-0600001390-e076205d2fb119edf751
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0cdi-0930000120-b1c594d779de36c33d38
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0900001380-9f87cc75ae768b595a69
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-272.39124
predicted
DeepCCS 1.0 (2019)
[M+H]+274.04446
predicted
DeepCCS 1.0 (2019)
[M+Na]+280.20126
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at November 12, 2015 16:46 / Updated at February 21, 2021 18:52